background
oseltamivir
zanamivir
recommend
treat
prevent
influenza
worldwid
brazil
offici
recommend
lack
econom
evalu
object
assess
effici
influenza
chemoprophylaxi
brazilian
context
assess
costeffect
oseltamivir
zanamivir
prophylaxi
influenza
high
risk
popul
compar
prophylaxi
perspect
brazilian
public
health
system
qualityadjust
life
year
qali
effect
data
base
literatur
review
cost
brazilian
real
brl
estim
offici
sourc
microcost
admiss
univers
hospit
use
decisiontre
model
consid
prophylaxi
prophylaxi
probabl
ambulatori
care
admiss
hospit
intens
care
patient
discharg
death
adher
advers
event
prophylaxi
includ
increment
costeffect
ratio
convert
unit
state
dollar
usd
uncertainti
assess
univari
probabilist
sensit
analysi
result
adher
prophylaxi
confid
interv
ci
advers
event
ci
rel
risk
infect
chemoprophylaxi
ci
incid
ci
ambulatori
care
ci
hospit
admiss
ci
hospit
mortal
ci
intens
care
unit
admiss
ci
intens
care
mortal
ci
qali
state
ci
inpati
ci
healthi
ci
death
advers
event
estim
affect
qali
ci
cost
chemoprophylaxi
brl
standard
deviat
sd
ambulatori
care
brl
sd
hospit
admiss
brl
sd
intens
care
admiss
brl
sd
advers
event
brl
sd
increment
costeffect
ratio
brl
usd
qali
usd
prevent
result
robust
sensit
analysi
influenza
prophylaxi
neuraminidas
inhibitor
recommend
world
health
organ
health
agenc
develop
underdevelop
countri
world
health
organ
world
health
organ
popul
risk
influenza
complic
includ
pregnant
postpartum
women
elderli
children
indigen
peopl
immunosuppress
person
health
profession
longterm
resid
among
other
uyeki
et
al
martinez
et
al
influenza
account
specimen
circul
first
month
influenza
pandem
world
health
organ
death
associ
respiratori
diseas
season
influenza
account
annual
iuliano
et
al
higher
burden
death
observ
less
develop
region
elderli
iuliano
et
al
complet
efficaci
data
neuraminidas
inhibitor
publish
updat
jefferson
et
al
jefferson
et
al
heneghan
et
al
effort
patient
data
phase
iii
clinic
trial
never
publish
previou
evid
could
bias
favor
chemoprophylaxi
jefferson
et
al
bias
conflict
interest
involv
research
influenza
treatment
prevent
translat
need
studi
drug
clinic
perform
health
system
financi
invest
jefferson
et
al
econom
evalu
take
consider
complet
efficaci
evid
avail
effici
influenza
chemoprophylaxi
also
absent
brazilian
context
recommend
fund
ministri
health
brasil
da
object
assess
costeffect
influenza
chemoprophylaxi
brazilian
public
health
system
target
popul
nonvaccin
vaccin
less
day
peopl
group
high
risk
influenza
complic
elderli
children
indigen
peopl
obes
individu
peopl
chronic
diseas
immunodefici
pregnant
puerper
women
health
care
laboratori
worker
expos
sampl
case
influenza
resid
nurs
home
inpati
outbreak
brasil
da
secretaria
de
em
unifi
health
system
sistema
de
su
public
univers
health
system
paim
et
al
su
public
health
sector
respons
primari
care
access
medicin
immun
program
complex
servic
cancer
treatment
hivaid
care
sanitari
regul
sentinel
surveil
monitor
influenza
mean
mandatori
report
flu
syndrom
sever
acut
respiratori
syndrom
world
health
organ
access
servic
larg
improv
sinc
system
birth
paim
et
al
despit
gradual
improv
decad
su
systemat
underfund
paim
et
al
adopt
su
perspect
consid
cost
su
context
exclud
societ
cost
absenc
work
patient
person
cost
involv
cost
drug
acquisit
health
care
servic
expenditur
case
symptomat
diseas
ambulatori
treatment
medic
consult
hospit
admiss
procedur
treatment
prophylaxisrel
advers
event
assess
influenza
chemoprophylaxi
aforement
highrisk
popul
compar
oseltamivir
zanamivir
prophylaxi
prophylaxi
oseltamivir
oral
antivir
drug
inhibit
neuraminidas
surfac
enzym
anatom
therapeut
chemic
atc
code
market
avail
scientif
support
experiment
infect
healthi
subject
influenza
b
epar
summari
public
drug
effect
prevent
influenza
infect
individu
expos
jefferson
et
al
also
abl
reduc
case
symptomat
influenza
within
household
dobson
et
al
well
time
allevi
symptom
infect
adult
oseltamivir
significantli
increas
incid
nausea
vomit
psychiatr
event
jefferson
et
al
adult
children
kg
take
mg
dose
oral
everi
h
day
children
weight
dosag
adjust
mgkg
infant
mg
children
kg
mg
kg
mg
kg
brasil
da
secretaria
de
em
zanamivir
antivir
select
neuraminidas
inhibitor
atc
code
administ
intranas
relenza
vitro
assay
show
low
concentr
drug
abl
inhibit
influenza
b
neuraminidas
symptom
durat
reduc
healthi
adult
median
reduct
day
day
mean
time
symptom
allevi
elderli
year
yearold
children
significantli
reduc
document
benefit
nonfebril
diseas
bodi
temperatur
relenza
zanamivir
employ
case
oral
oseltamivir
feasibl
adult
children
older
year
receiv
two
mg
inhal
per
day
day
brasil
da
secretaria
de
em
evalu
outcom
influenza
prophylaxi
base
durat
influenza
infect
less
day
discount
rate
appli
qualityadjust
life
year
qali
primari
outcom
willingnesstopay
wtp
threshold
consid
brazilian
real
brl
per
qali
soarez
nova
prevent
influenza
also
assess
secondari
outcom
data
oseltamivir
zanamivir
effect
prevent
symptomat
flu
complic
gather
search
literatur
held
march
follow
search
strategi
employ
medlin
via
pubm
databas
oseltamivir
tamiflu
zanamivir
relenza
neuraminidas
inhibitor
influenza
clinic
trial
filter
systemat
filter
cost
econom
strategi
adjust
embas
scopu
cochran
librari
databas
addit
search
perform
ascertain
effect
cost
data
brazilian
scenario
result
import
covid
www
covidenceorg
identifi
duplic
pair
select
perform
two
independ
research
systemat
review
random
clinic
trial
observ
studi
includ
complementari
nonsystemat
search
perform
order
gather
specif
data
preval
hospit
death
hospit
variabl
includ
model
inform
also
collect
su
electron
system
whenev
need
estim
differ
studi
avail
randomeffect
metaanalysi
perform
use
stata
version
assess
qualiti
includ
studi
use
standard
instrument
measur
tool
assess
systemat
review
amstar
systemat
review
shea
et
al
newcastleottawa
scale
cohort
casecontrol
studi
well
et
al
joanna
brigg
institut
checklist
preval
studi
munn
et
al
cost
oseltamivir
zanamivir
acquisit
obtain
purchas
data
provid
brazilian
ministri
health
use
inform
made
avail
pharmaceut
assist
depart
health
care
assist
cost
obtain
su
reimburs
system
http
sigtapdatasusgovbrtabelaunificadaappsec
inicio
jsp
consid
dosag
administr
accord
brazilian
guidelin
brasil
da
secretaria
de
em
health
expenditur
obtain
microcost
inpati
admit
treatment
clinic
hospit
univers
campina
campina
pauloa
high
complex
hospit
cost
calcul
brl
acquisit
valu
cost
gather
literatur
previou
year
correct
use
brazilian
consum
price
index
de
ao
consumidor
ipca
http
indicadoresprecosinpcipcadefaultinpcshtm
obtain
increment
costeffect
ratio
icer
convert
unit
state
dollar
usd
use
exchang
rate
juli
st
provid
brazil
central
bank
usd
brl
http
id
quotat
treeag
pro
softwar
use
build
decisiontre
model
two
scenario
consid
chemoprophylaxi
chemoprophylaxi
scenario
follow
probabl
assess
infect
ambulatori
care
hospit
admiss
intens
care
admiss
patient
discharg
death
prophylaxi
scenario
includ
adher
prophylaxi
incid
advers
event
figur
cost
outcom
calcul
consid
flu
case
influenza
type
halfcycl
correct
use
calcul
cost
case
death
final
outcom
clinic
plausibl
evalu
infecti
diseas
specialist
doctor
part
research
team
mrr
experi
influenza
manag
consid
symptomat
patient
would
seek
outpati
care
hospit
admiss
assum
probabl
seek
ambulatori
care
admiss
intens
care
unit
probabl
peopl
admit
hospit
death
assum
possibl
peopl
admit
hospit
intens
care
subject
develop
flu
consid
healthi
sequela
late
effect
influenza
consid
uncertainti
model
estim
accord
variat
adopt
paramet
tornado
diagram
minimum
maximum
valu
use
univari
sensit
analysi
sensitivityenhanc
model
paramet
chosen
bestand
worstcas
scenario
analys
probabilist
sensit
analysi
perform
use
mont
carlo
employ
simul
count
threshold
analysi
identifi
maximum
cost
technolog
paramet
unchang
ceteri
paribu
use
variabl
distribut
beta
distribut
adopt
probabl
outcom
gamma
cost
lognorm
rel
risk
bilck
et
al
studi
approv
univers
campina
ethic
committe
report
number
issu
octob
th
studi
exempt
consent
procedur
patient
data
would
medic
record
probabl
efficaci
adopt
describ
tabl
metaanalysi
clinic
trial
prophylaxi
oseltamivir
zanamivir
gener
popul
jefferson
et
al
highqual
review
c
risk
popul
mean
sd
metaanalysi
incid
studi
febril
acut
respiratori
syndrom
household
lau
et
al
criticallylow
qualiti
review
c
prophylaxi
adher
consid
accord
adher
data
health
profession
expos
viru
pandem
upjohn
et
al
incid
advers
event
among
adher
prophylaxi
estim
base
incid
headach
nausea
psychiatr
eventsth
frequent
signific
advers
event
appendix
risk
infect
highrisk
popul
consid
base
incid
symptomat
infect
among
household
contact
infect
patient
lau
et
al
rel
risk
infect
prophylaxi
consid
confid
interv
ci
accord
metaanalysi
prophylaxi
antivir
jefferson
et
al
data
sheet
sinc
scientif
evid
show
efficaci
prevent
complic
proxi
seek
medic
care
hospit
intens
care
admiss
death
influenza
jefferson
et
al
jefferson
et
al
heneghan
et
al
variabl
probabl
prophylaxi
prophylaxi
branch
probabl
seek
medic
care
ambulatori
care
incid
symptomat
ill
experiment
influenza
infect
carrat
et
al
assum
peopl
develop
symptom
would
seek
medic
care
incid
hospit
intens
care
admiss
hospit
intens
care
mortal
base
brazilian
studi
held
pandem
duart
et
al
lenzi
et
al
calmona
complet
qualiti
assess
studi
provid
data
model
avail
data
sheet
qali
infect
manag
outpati
servic
admit
hospit
intens
care
base
studi
patient
infect
pandem
hollmann
et
al
advers
event
reduc
qali
appendix
qali
healthi
state
mean
qali
measur
two
populationbas
brazilian
studi
zimmermann
et
al
silva
et
al
qali
death
tabl
cost
prophylaxi
brl
base
averag
expenditur
brazilian
ministri
health
antivir
appendix
b
treatment
prophylaxi
advers
cost
brl
calcul
cost
main
advers
event
headach
nausea
psychiatr
event
weight
advers
event
incid
appendix
outpati
care
cost
brl
accord
su
reimburs
urgent
care
consult
cost
hospit
admiss
estim
brl
intens
care
brl
tabl
prophylaxi
scenario
undomin
prophylaxi
absolut
domin
tabl
increment
cost
prophylaxi
brl
qali
increas
result
icer
brl
per
qali
usd
secondari
outcom
prevent
infect
increment
qali
icer
brl
per
prevent
case
usd
tornadodiagram
sensit
analysi
demonstr
robust
model
use
expect
interv
variabl
figur
none
variabl
chang
costeffect
profil
technolog
given
adopt
wtp
threshold
brl
icer
remain
robust
bestand
worstcas
scenario
analysi
highest
impact
variabl
tornado
tabl
threshold
analysi
led
brl
limit
chemoprophylaxi
costeffect
probabilist
sensit
analysi
icer
would
fourth
quadrant
higher
effect
lower
cost
icer
first
quadrant
higher
cost
effect
probabl
technolog
wtp
threshold
brl
tabl
figur
lindner
et
al
araujo
et
al
weight
incid
advers
event
jefferson
et
al
prophylaxi
compar
prophylaxi
costsav
context
brazilian
health
system
qali
prevent
outcom
mean
cost
calcul
microcost
align
previou
brazilian
studi
estim
cost
hospit
admiss
influenza
chemoprophylaxi
reduc
cost
increas
effect
influenza
prevent
effect
qali
howev
may
clinic
irrelev
case
prevent
singl
influenza
case
mean
prophylaxi
could
save
nearli
brl
time
brazil
offici
wtp
threshold
soarez
nova
whether
present
repres
costeffect
altern
subject
debat
effect
neuraminidas
inhibitor
prophylaxi
came
clinic
trial
exposur
treatment
onset
highli
control
effect
chemoprophylaxi
limit
strict
condit
accord
mathemat
model
comput
simul
stockpil
situat
question
parraroja
et
al
despit
protocol
start
drug
first
hour
postexposur
pragmat
clinic
trial
reveal
late
initi
oseltamivir
hospit
set
without
reduct
clinic
failur
among
assess
group
ramirez
et
al
potenti
unrealist
efficaci
data
may
inflat
effect
prophylaxi
obtain
influenza
prevent
efficaci
data
systemat
review
carri
offspr
cochran
collabor
bmj
campaign
obtain
complet
clinic
trial
data
roch
drug
manufactur
campaign
effort
led
public
systemat
review
updat
chang
result
jefferson
et
al
jefferson
et
al
heneghan
et
al
sixti
percent
patient
data
phase
iii
clinic
trial
never
publish
suggest
previouslypublish
research
bias
favor
technolog
jefferson
et
al
public
bia
reduc
clinic
trial
drug
taken
consider
effort
jefferson
et
al
jefferson
et
al
heneghan
et
al
probabl
base
data
studi
held
influenza
pandem
period
mark
greater
virul
influenza
brazil
worldwid
da
case
sever
acut
respiratori
syndrom
brazil
reach
per
inhabit
later
occurr
decreas
case
per
inhabit
final
reach
influenza
vaccin
part
program
vaccin
elderli
year
age
sinc
use
expand
peopl
year
age
pregnant
women
children
six
month
two
year
age
indigen
peopl
health
worker
includ
sinc
vaccin
coverag
hover
da
probabl
adopt
model
led
sever
consequ
influenza
favor
prophylaxi
perform
assum
patient
symptom
would
seek
medic
care
therefor
consid
outofpocket
expens
case
patient
would
treat
without
seek
medic
consult
econom
studi
dengu
brazil
godoi
et
al
adher
prophylaxi
base
health
profession
pandem
period
greater
concern
infect
assumpt
use
data
pandemia
brought
conserv
scenario
probabl
reflect
current
scenario
peopl
vaccin
greater
herd
immun
grant
determinist
probabilist
sensit
analysi
attest
robust
costeffect
probabl
infect
hospit
admiss
death
rang
partial
circumv
limit
primari
outcom
studi
base
qali
spanish
context
due
lack
util
data
influenza
brazil
qali
healthi
state
base
brazilian
popul
data
zimmermann
et
al
silva
et
al
evalu
prevent
influenza
secondari
outcom
involv
popul
percept
favor
prophylaxi
brazilian
protocol
influenza
state
chemoprophylaxi
administ
nonvaccin
vaccin
less
day
peopl
brasil
da
secretaria
de
em
data
effect
antivir
drug
segreg
vaccin
statu
avail
specif
analysi
targetpopul
vaccin
effect
influenza
vaccin
show
reduc
healthcar
util
elderli
doyonplourd
et
al
well
antibiot
usag
health
adult
buckley
et
al
maintain
consist
nation
guidelin
ignor
effect
vaccin
model
may
favor
need
effect
chemoprophylaxi
studi
similar
previou
health
econom
evalu
influenza
chemoprophylaxi
also
adopt
decisiontre
model
time
horizon
shorter
one
year
favor
prophylaxi
canadian
health
system
postexposur
prophylaxi
institution
vaccin
elderli
domin
prevent
influenzalik
ill
compar
prophylaxi
risebrough
et
al
evalu
base
three
altern
prophylaxi
amantadin
prophylaxi
oseltamivir
prophylaxi
predict
viral
resist
advers
effect
amantadin
branch
influenzalik
ill
complic
death
surviv
treatment
hospit
institut
risebrough
et
al
research
sponsor
oseltamivir
manufactur
f
hoffmannla
roch
unit
kingdom
postexposur
prophylaxi
interfamili
contact
probabl
costeffect
context
nation
health
system
consid
cost
data
sander
et
al
model
compar
prophylaxi
prophylaxi
without
oseltamivir
treatment
case
symptomat
influenza
predict
complic
outpati
care
hospit
admiss
recoveri
death
assess
qali
avoid
case
influenzalik
ill
probabilist
sensit
analysi
attest
robust
model
sander
et
al
studi
also
sponsor
f
hoffmannla
roch
last
author
employe
compani
unit
state
analysi
postexposur
prophylaxi
oseltamivir
children
year
costeffect
perspect
societi
payer
cost
talbird
et
al
model
compar
prophylaxi
prophylaxi
predict
develop
influenza
hospit
admiss
outpati
care
death
surviv
talbird
et
al
research
commiss
roch
last
author
employe
nation
health
system
unit
kingdom
fund
systemat
review
efficaci
effect
season
postexposur
prophylaxi
subsequ
analysi
costeffect
use
amantadin
oseltamivir
zanamivir
vaccin
nonvaccin
individu
tappenden
et
al
six
subgroup
consid
children
adult
elderli
highrisk
healthi
state
use
cost
data
influenzalik
ill
search
outpati
care
antivir
treatment
complic
death
surviv
consid
analysi
tappenden
et
al
model
predict
advers
effect
amantadin
vaccin
prophylaxi
abandon
rang
postexposur
prophylaxi
british
poundsqali
nonvaccin
children
elderli
none
econom
assess
consid
herd
immun
advers
event
studi
drug
complet
efficaci
data
lower
risk
public
bia
jefferson
et
al
jefferson
et
al
heneghan
et
al
postexposur
prophylaxi
influenza
costsav
context
brazilian
public
health
system
current
brazilian
guidanc
influenza
prevent
support
find
lack
nation
efficaci
effect
data
notic
oseltamivir
zanamivir
alreadi
incorpor
purpos
chang
current
guidelin
unnecessari
studi
approv
octob
unicamp
ethic
committe
de
certif
number
studi
exempt
consent
procedur
data
patient
medic
record
lv
tg
ms
design
work
lv
collect
data
lv
tg
analys
draft
work
ms
es
mr
interpret
data
revis
work
critic
author
approv
version
publish
agre
account
aspect
work
studi
fund
haoc
proadi
su
nonfinanci
support
provid
clinic
hospit
faculti
pharmaceut
scienc
univers
campina
